The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions has entered into a new agreement with ValiRx plc (AIM:VAL), a clinical stage drug development Company. The new agreement supersedes the agreement between Physiomics and ValiRx which was announced on 13 September 2011.
15 Feb 2021
Physiomics deepens its relationship with ValiRx and agrees 6% revenues share (up to £6m) on clinical stage asset.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Physiomics deepens its relationship with ValiRx and agrees 6% revenues share (up to £6m) on clinical stage asset.
Physiomics Plc (PYC:LON) | 1.3 0 0.0% | Mkt Cap: 1.76m
- Published:
15 Feb 2021 -
Author:
Derren Nathan -
Pages:
7
The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions has entered into a new agreement with ValiRx plc (AIM:VAL), a clinical stage drug development Company. The new agreement supersedes the agreement between Physiomics and ValiRx which was announced on 13 September 2011.